Try our beta test site

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

This study has been completed.
Astex Pharmaceuticals
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group ) Identifier:
First received: June 21, 2012
Last updated: October 25, 2016
Last verified: February 2015